MetaCap

Novo Nordisk A/S (NVO) vs Novartis (NVS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Novartis (NVS) has outperformed Novo Nordisk A/S (NVO) over the past year, gaining 18.2% versus a loss of 20.6%. Over five years, NVS leads with a +86.5% price change compared with -30.1% for NVO. Novartis is the larger company by market cap ($284.18 billion vs $166.69 billion), about 1.7 times the size.

On valuation, Novo Nordisk A/S trades at a lower forward P/E (10.8x vs 15.1x for Novartis). Novo Nordisk A/S offers the higher dividend yield (30.94% vs 3.10%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NVO-20.60%NVS+18.19%
+37%+4%-29%
Nov 21, 20251 yearNov 20, 2026
NVO-33.57%NVS+84.26%
+160%+57%-46%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NVO versus NVS key metrics
MetricNVONVS
Share price$37.82$150.47
Market cap$166.69B$284.18B
1-day change-2.70%-0.50%
YTD return-25.67%+9.14%
1-year return-20.60%+18.19%
5-year return-30.07%+86.46%
P/E ratio (TTM)9.5528.72
Forward P/E10.7715.15
EPS (TTM)$3.96$5.24
Dividend yield30.94%3.10%
Annual dividend$11.70$4.67
Net income (latest FY)—$13.98B
52-week high$64.16$170.46
52-week low$35.12$126.50
Distance from 52-week high-41.05%-11.73%
Analyst consensusholdhold
Avg. price target upside+20.28%+4.41%
Average volume12.59M2.18M
Shares outstanding3.33B1.89B
Employees68,79475,267
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NVS has outperformed NVO by 38.8 percentage points over the past year.
  • Novartis trades at a higher earnings multiple (28.7x vs 9.6x trailing P/E).
  • Novo Nordisk A/S offers a meaningfully higher dividend yield (30.94% vs 3.10%).

About Novo Nordisk A/S

NVO stock →

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 68,794 employees

About Novartis

NVS stock →

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 75,267 employees

NVO vs NVS FAQ

Which is bigger, Novo Nordisk A/S or Novartis?

Novartis (NVS) is larger, with a market capitalization of $284.18B compared with $166.69B for Novo Nordisk A/S (NVO).

Which stock has performed better over the past year, NVO or NVS?

NVS returned +18.19% over the past 12 months, compared with -20.60% for NVO (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, NVO or NVS?

NVO has the lower trailing P/E at 9.6, versus 28.7 for NVS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Novo Nordisk A/S or Novartis?

Novo Nordisk A/S has the higher yield at 30.94%, compared with 3.10% for Novartis.

Are Novo Nordisk A/S and Novartis in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons